Lumigan (bimatoprost ophthalmic solution) 0.01%, 7.5 mL bottle, Rx only, Allergan Irvine, CA 9261...

FDA Drug Recall #D-0667-2017 — Class III — March 16, 2017

Recall Summary

Recall Number D-0667-2017
Classification Class III — Low risk
Date Initiated March 16, 2017
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Allergan Sales, LLC
Location Waco, TX
Product Type Drugs
Quantity 56,878 bottles

Product Description

Lumigan (bimatoprost ophthalmic solution) 0.01%, 7.5 mL bottle, Rx only, Allergan Irvine, CA 92612, NDC 0023-3205-08.

Reason for Recall

Failed Impurities/Degradation Specifications

Distribution Pattern

Nationwide in the US

Lot / Code Information

Lot #: 92577, Exp. JUN 2018

Other Recalls from Allergan Sales, LLC

Recall # Classification Product Date
D-1056-2019 Class II Combigan (brimonidine tartrate/timolol maleate ... Mar 19, 2019
D-0078-2018 Class III Lumigan (bimatoprost ophthalmic solution) 0.01%... Oct 19, 2017
D-0077-2018 Class III Combigan (brimonidine tartrate/timolol maleate ... Oct 19, 2017
D-0929-2017 Class II Blephamide (sulfacetamide sodium and prednisolo... May 1, 2017
D-0099-2017 Class II TAZORAC (tazarotene) Gel 0.05%, Rx only, For De... Jun 30, 2016

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.